Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Ticagrelor MeSH Descriptor Data 2026


MeSH Heading
Ticagrelor
Tree Number(s)
D03.633.100.759.590.138.806
D13.570.583.138.806
D13.570.800.096.815
Unique ID
D000077486
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077486
Scope Note
An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.
Entry Term(s)
3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AZD 6140
AZD-6140
AZD6140
Brilinta
Brilique
Pharm Action
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Registry Numbers
GLH0314RVC
0
CAS Type 1 Name
1,2-cyclopentanediol, 3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-1,2,3-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-
Public MeSH Note
2019; TICAGRELOR was indexed under ADENOSINE/analogs&derivatives 2005-2018
History Note
2019 (2005)
Date Introduced
2019/01/01
Last Updated
2019/01/01
Ticagrelor Preferred
AZD 6140 Narrower
Brilique Narrower
3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol Narrower
Brilinta Narrower
page delivered in 0.139s